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esses: fedemartinon@mSummary This is the first study aiming to assess the effects of heliox in
combination with nasal continuous positive airway pressure (Hx-nCPAP) as a rescue
treatment in infants with refractory acute bronchiolitis.
Fifteen out of 78 infants with acute bronchiolitis consecutively admitted to PICU
fulfilled the inclusion criteria: clinical score X5 or arterial oxygen saturation
(SatO2)p92% or PCO2450mmHg, despite supportive therapy, nebulized L-epinephr-
ine, and heliox therapy through non-rebreathing reservoir facemask. Hx-nCPAP was
added as a rescue treatment. Baseline mean (standard deviation) values were:
clinical score of 7.4 (1.2) points; PCO2 of 63.8 (12)mmHg; respiratory rate (RR) of
66.4 (9.9); and SatO2 of 88.6 (4.7)%.
Clinical score, PCO2, RR and SatO2 improved during the study time (Po0.05).
After 1 h the mean clinical score decreased by 1.5 points, with a total average
decrease of 3.5 points at the end of the study period. The mean PCO2 diminished by 9
and 25mmHg, after 1 and 48 h, respectively. The mean RR decreased 13 rpm after 1 h
and 30 rpm after 48 h. The Hx-nCPAP total duration ranged from 2 to 14 days. Only
one patient required endotracheal intubation. No adverse effects were detected. All
patients recovered fully.
In conclusion, Hx-nCPAP improved the clinical score, decreased the tachypnea
and enhanced the CO2 elimination of infants with refractory acute bronchiolitis
within 1 h of administration, in a safe and non-invasive manner. Hx-nCPAP might
reduce the need for endotracheal intubation. Further studies are needed.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Bronchiolitis is a major reason for hospitalization in
infants.1,2 It can lead to respiratory insufficiency in
more than 50% of those patients admitted to the
pediatric intensive care unit (PICU).1,2 Although
several therapeutic interventions have been as-
sessed, no proven successful treatment has been
achieved.2–4
It has been recently suggested that heliox
therapy could be useful in the treatment of infants
with bronchiolitis.5,6 It has also been indicated that
non-invasive ventilation (NIV), and specifically,
nasal continuous positive pressure (nCPAP), may
improve the respiratory status of children with
hypoxemic respiratory failure.7,8 Extrapolating
from the existing data for adult patients,9,10 and
considering the theoretical fundamentals of both
therapies,5–8,11 the combination of heliox and NIV
might be useful in pediatric patients. To our
knowledge no data on the combined use of NIV
and heliox in bronchiolitis patients have been
previously reported.
The aim of this exploratory study was to assess
the effects on ventilation, respiratory rate and
clinical score, of administering heliox (Hx) with
nCPAP (Hx-nCPAP) as a rescue treatment in infants
with refractory acute bronchiolitis.Materials and methods
Study design
A preliminary prospective, clinical, interventional,
observational, single-center, uncontrolled study
was planned. The study was approved by the
Institutional Review Board, and written informed
parental consent was obtained in all cases before
enrollment.
Study subjects
Infants 1 month to 1 year old, admitted to the PICU
from January 2002 to February 2004, with respira-
tory syncytial virus (RSV) bronchiolitis and: Modified Wood’s Clinical Asthma Score
(M-WCAS)X5,6 or arterial oxygen saturation p92%, or
 PCO2450mmHg
despite optimized supportive therapy, nebulized
L-epinephrine and heliox therapy through non-
rebreathing reservoir facemask for at least 1 h,were eligible for the study. Patients with underlying
chronic lung disease were not suitable.
Diagnostic criteria of bronchiolitis included ta-
chypnea, cough, prolonged expiratory time,
wheezing, rales, chest retractions, and hyperinfla-
tion of the lungs on chest radiographs.6 RSV
infection was confirmed by enzyme-linked immu-
noadsorbent assay of nasal secretions. Moderate-
to-severe respiratory distress was defined as a
M-WCAS of 5 or greater.6
During the study period, 78 infants with severe
acute bronchiolitis were admitted to our PICU.
Fifteen of them, 8 males and 7 females, fulfilled
the inclusion criteria and were enrolled in the
study. A mean of 8.1 (9.8) h have elapsed since they
were admitted to PICU. Their median age was 2
(range 1–7) months. One patient had underlying
heart disease, and 3 patients had suffered from
bronchiolitis in the preceding 2 months.
All patients received one dose of nebulized
epinephrine at the start of the study; it was then
administered at 2–6 h intervals at the discretion of
one of the three physicians responsible for the
study. No patient received any nebulized medica-
tions other than epinephrine or systemic corticos-
teroids, before enrollment or during the study.
No patient required sedation in order to tolerate
Hx-nCPAP.
Definitions
Nebulized L-epinephrine: 3mg/dose each 2–6 h, as
needed.
Heliox therapy11: helium-70%/oxygen-30% mix-
ture, warmed and humidified was administered at
10–15 lpm through non-rebreathing reservoir face-
mask. A central wall-supply of dry heliox with a
prefixed concentration (70%-He and 30%-O2) was
used (Air Liquide Medicinals, Madrid, Spain).
Intervention: H-nCPAP logistics
Those patients who fulfilled the inclusion criteria
received nCPAP with heliox (70%-helium and 30%-
oxygen) (Hx-nCPAP). The heliox source was directly
connected to the air inlet of a non-invasive positive
pressure ventilator (Infant Flow Advances, Elec-
tromedical Medicine, United Kingdom). The venti-
lator was settled in CPAP mode without backup rate
and with a starting pressure of 5 cm H2O. The heliox
flow was adjusted for the desired initial CPAP
pressure using the air–oxygen flow meter of the
device. The actual heliox flow was calculated by
applying standard conversion factors.11 The heliox
mixture was delivered to the patient previously
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device (MR730 Humidification systems; Fisher &
Paykel Healthcare Spain, Madrid, Spain). Either
nasal prongs or nasal mask were selected for Hx-
nCPAP delivery, according to patient’s size and
comfort, and at the physician’s discretion. CPAP
pressure and FiO2 were adjusted to maintain SatO2
above 94% with the minimum FiO2 possible, in order
to deliver the highest amount of helium to the
patient. When the FiO2 needed was higher than
0.4, the pressure was increased in 1 cm H2O
increments. When FiO2p0.3, PCO2p50mmHg and
a clinical score o5 were maintained for 6 h, the
Hx-nCPAP treatment was withdrawn.
Hx-nCPAP treatment was considered a failure
when, SatO2 was below 92% with CPAP above 10 cm
H2O and FiO2 was above 0.6, or PCO2 was
persistently above 60mmHg, or when the patient
did not tolerate the technique, or if the patients’
clinical condition acutely deteriorated at any time
during the study. In these circumstances patients
were returned to conventional therapy, re-evalu-
ated and considered for endotracheal intubation
and invasive mechanical ventilation.Measurements and outcomes
M-WCAS, PCO2, SatO2, and respiratory rate (RR)
values were recorded at baseline, then at 1 h
intervals for 6 h, and afterwards, at 8 h intervals,
until Hx-nCPAP therapy was discontinued. Data
obtained during the first 48 h were analyzed.
Demographic data, duration of heliox therapy,
need for endotracheal intubation, and administra-
tion of concurrent therapies were collected for
each patient.
The principal outcome measures were the
change in M-WCAS, RR and PCO2 levels. For clinical
scoring, we followed a previously applied metho-
dology.6 The PCO2 was continuously monitoredTable 1 Summary of patient’s data during the first 48 h
Basal 1 h 6 h
M-WCAS 7.4 (1.2) 6.0 (0.8) 5.5
RR (rpm) 66.4 (9.9) 52.7 (5.4) 43.
PCO2 (mmHg) 63.8 (12.0) 54.8 ( 9.5) 50.
SatO2 (%) 88.6 (4.7) 95.3 (2.4) 95.
FiO2 36 (6.1) 35 (5.6) 32
CPAP (cmH2O) 7.4 (1.2) 7.2 (1.1) 6 (1
M-WCAS, Modified-Wood clinical asthma score; SatO2, arterial ox
minute; CPAP, continuous positive airway pressure.
aData are expressed as mean (standard deviation). Differences i
Friedman one-way analysis of variance.by means of earlobe transcutaneous technique
(Toscas, Linde Medical Sensors, Switzerland) and
checked at recording points by blood gas analysis.
The SatO2 was continuously monitored using pulse
oximetry (Radicals, Massimo SET pulse oximeter,
California, USA). Any adverse event potentially
related to the Hx-nCPAP treatment was registered.
Patient tolerance of the technique was assessed
primarily by the investigator and afterwards by the
nurse in attendance. Any eventual need of sedation
was also recorded. All patients were followed up
for at least 6 months after discharge.Statistical analysis
The distributions of trial variables were assessed by
means of Shapiro–Wilk test. Friedman’s one-way
analysis of variance was used to assess changes in
variables over the course of the study. The
differences between each measurement interval
were assessed by post hoc analysis with Wilcoxon
matched-pairs signed-ranks test, employing a Bon-
ferroni correction. Statistical significance was
indicated by Po0.05. Data are presented as mean
(standard deviation) unless otherwise indicated. All
statistical analyses were performed using SPSS
software 12.0 version (Chicago, IL).Results
Clinical score, SatO2, RR and PCO2 improved over
the course of the study (Po0.05) (Table 1). At
baseline, mean clinical score was 7.4 (1) points.
After 1 h the mean clinical score had decreased by
1.5 points (Po0.05). The score continued to
improve, with a total average decrease of 3.5
points at the end of the study period (Po0.05).
The initial mean PCO2 was 63.8 (12)mmHg. After
1 h, an average decrease of 9mmHg was achievedof therapy with Hx-nCPAP.a
24 h 48 h
(0.9) 4.6 (1.0) 3.9 (0.7) Po0.05
6 (5.6) 36.2 (3.4) 31.5 (3.5) Po0.05
1 (10.2) 43.2 (7.9) 38.2 (6.4) Po0.05
6 (2.8) 97.6 (1.8) 97.6 (2.0) Po0.05
(4.1) 30 (2.1) 30 (1.5)
) 5.4 (0.5) 5.1 (0.3)
ygen saturation; RR, respiratory rate; rpm, respirations per
n measured parameters over time were assessed by means of
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significantly at all the time intervals, with a total
average decrease of 25mmHg at the end of the
observation period (Po0.05).
Mean RR was 66.4 (10) rpm at the beginning of
the study, diminished by 13 rpm after 1 h, with a
final average decrease of 30 rpm (Po0.05).
Baseline mean SatO2 was 88.6 (4)%, and had
improved by 7% to 95.3 (2.4)% during the first hour
(Po0.05). A mean of 7.4 (1.2) cmH2O of CPAP and
36 (6.1)% of FiO2 were initially required to elevate
SatO2 above 94%. Mean SatO2 remained stable
above 94% for the rest of the observation period,
with a final average increase of 9% (Po0.05).
Total Hx-nCPAP duration ranged from 2 to 14 days
(6.1 (3.3) days). No adverse effects attributable to
Hx-nCPAP were detected. All patients tolerate the
technique without sedation. One patient with an
initial positive response to Hx-nCPAP, worsened
after 3 days due to Escherichia coli superinfection
and secondary septic shock. He required endotra-
cheal intubation and mechanical ventilation for
3 days, being weaned without incident. All the
patients fully recovered and continued to do well
after between 8 and 28 months follow-up. No
patient required PICU re-admission after being
discharged.Discussion
Our results suggest heliox therapy in combination
with nasal continuous positive pressure is a safe and
effective option for the management of infants
with unresponsive acute bronchiolitis. The use of
Hx-nCPAP reduced respiratory distress, demon-
strated by both the improvement in clinical score
and the reduction in tachypnea. Ventilation also
improved, reflected by the marked reduction seen
in CO2 levels.
Hx-nCPAP may have also helped avoid endotra-
cheal intubation and mechanical ventilation in
some patients. According to their baseline data,
all of our patients treated with Hx-nCPAP fulfilled
the usual criteria for endotracheal intubation and
assisted ventilation12; however, with the applica-
tion of Hx-nCPAP intubation was prevented in all
but one case. A literature search reveals that
25–60% of those infants with bronchiolitis admitted
to PICU may eventually need intubation and
invasive ventilatory support.1,2,13–17 Even accepting
the influence of other factors different to Hx-nCPAP
treatment, including distinct PICU admission poli-
cies or particular intubation criteria, in our series
only 1 out of 78 (1.3%) of cases required invasivemechanical ventilation (95% exact confidence
interval ¼ 0.2–6.9%), a figure strikingly lower than
previously reported.1,2,13–17
Only three studies to date have tried to assess
the role of heliox in a bronchiolitis setting: two
with facemask in spontaneously breathing infants5,6
and another one in mechanically ventilated pa-
tients.18 The majority of the literature concerning
Hx-nCPAP concentrates on adults with acute ex-
acerbations of chronic pulmonary obstructive dis-
ease.9,10 Similarly to the effects found in our
children, these studies suggest that Hx-nCPAP can
safely improve gas exchange and reduce symptoms
in such patients.9,10
From our preliminary clinical experience, we
could postulate that Hx-nCPAP noticeably has
manifold complementary, if not synergistic,
effects. It is possible that nCPAP could contribute
to a decrease in the workload on the inspiratory
muscles, prevent or relieve atelectasis, avoid
airway collapse and promote heliox distribution.
Heliox could further alleviate respiratory work,
enhance carbon dioxide elimination, and increase
expiratory flow. Applying nCPAP may reduce
the needed FiO2 in these children, augmenting
the actual helium concentration delivered to the
patient.
There are limitations to our study including: its
small sample size, open observational design, lack
of control group, and the use of changes in the
clinical score as one of the primary outcome
measures. Despite their known limitations, clinical
scores are often used as a research tool and this
particular scoring system has been previously
validated.6 The study design did not allow us to
determine the exact contribution of either heliox
or nCPAP to the final effect; however, this was not
its purpose. Our study shows a potential beneficial
effect of Hx-nCPAP in these patients, along with
good patient safety and tolerability. We believe
that our results justify moving on to randomized
clinical trials involving Hx-nCPAP. Apart from the
need to estimate treatment effects, other issues
need addressing such as the optimal time of
intervention, ideal starting and maintenance para-
meters, the duration of treatment, and the detec-
tion of non-responders.
In conclusion, the combination of heliox and
nCPAP may be effective in infants with acute severe
bronchiolitis, within the first hour of its adminis-
tration and, in a safe and non-invasive manner. Hx-
nCPAP may provide time for other therapeutic
agents to work or for the disease to resolve
naturally, avoiding more aggressive interventions.
Further prospective studies are now needed
to ascertain the role of this therapy in the
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precise contribution of either heliox or nCPAP to
this beneficial response.Acknowledgments
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